Cargando…

RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form

BACKGROUND: A simple, precise, accurate, and rapid reverse phase-high performance liquid chromatography (RP-HPLC) method with UV-Visible detector has been developed and subsequently validated for the simultaneous determination of tenofovir disoproxil fumarate (TDF), lamivudine (LAMI), and efavirenz...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhavsar, Dhara S., Patel, Bhavini N., Patel, Chhaganbhai N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658085/
https://www.ncbi.nlm.nih.gov/pubmed/23781482
http://dx.doi.org/10.4103/2229-4708.103876
_version_ 1782270224177823744
author Bhavsar, Dhara S.
Patel, Bhavini N.
Patel, Chhaganbhai N.
author_facet Bhavsar, Dhara S.
Patel, Bhavini N.
Patel, Chhaganbhai N.
author_sort Bhavsar, Dhara S.
collection PubMed
description BACKGROUND: A simple, precise, accurate, and rapid reverse phase-high performance liquid chromatography (RP-HPLC) method with UV-Visible detector has been developed and subsequently validated for the simultaneous determination of tenofovir disoproxil fumarate (TDF), lamivudine (LAMI), and efavirenz (EFV) in their combined tablet dosage form. MATERIALS AND METHODS: The separation was based on the use of a Kromasil C(18) analytical column (150 × 4.6 mm, i.d., 5 μm). The mobile phase consisted of a mixture of 70 volumes of methanol and 30 volumes of 10 mM phosphate buffer (pH 5.0). The separation was carried out at 40°C temperature with a flow rate of 1 ml/min. RESULTS: Quantitation was achieved with UV detection at 254 nm, with linear calibration curves at concentration ranges of 1–6 μg/ml for TDF and LAMI and 2–12 μg/ml for EFV. The recoveries obtained were 99.46–101.36% for LAMI, 99.57–101.42% for TDF, and 99.96–100.87 for EFV. CONCLUSION: The method was validated according to International conference of harmonisation guidelines in terms of accuracy, precision, specificity, robustness, limits of detection and quantitation, and other aspects of analytical validation.
format Online
Article
Text
id pubmed-3658085
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36580852013-06-18 RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form Bhavsar, Dhara S. Patel, Bhavini N. Patel, Chhaganbhai N. Pharm Methods Original Article BACKGROUND: A simple, precise, accurate, and rapid reverse phase-high performance liquid chromatography (RP-HPLC) method with UV-Visible detector has been developed and subsequently validated for the simultaneous determination of tenofovir disoproxil fumarate (TDF), lamivudine (LAMI), and efavirenz (EFV) in their combined tablet dosage form. MATERIALS AND METHODS: The separation was based on the use of a Kromasil C(18) analytical column (150 × 4.6 mm, i.d., 5 μm). The mobile phase consisted of a mixture of 70 volumes of methanol and 30 volumes of 10 mM phosphate buffer (pH 5.0). The separation was carried out at 40°C temperature with a flow rate of 1 ml/min. RESULTS: Quantitation was achieved with UV detection at 254 nm, with linear calibration curves at concentration ranges of 1–6 μg/ml for TDF and LAMI and 2–12 μg/ml for EFV. The recoveries obtained were 99.46–101.36% for LAMI, 99.57–101.42% for TDF, and 99.96–100.87 for EFV. CONCLUSION: The method was validated according to International conference of harmonisation guidelines in terms of accuracy, precision, specificity, robustness, limits of detection and quantitation, and other aspects of analytical validation. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3658085/ /pubmed/23781482 http://dx.doi.org/10.4103/2229-4708.103876 Text en Copyright: © Pharmaceutical Methods http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Bhavsar, Dhara S.
Patel, Bhavini N.
Patel, Chhaganbhai N.
RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
title RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
title_full RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
title_fullStr RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
title_full_unstemmed RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
title_short RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
title_sort rp-hplc method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658085/
https://www.ncbi.nlm.nih.gov/pubmed/23781482
http://dx.doi.org/10.4103/2229-4708.103876
work_keys_str_mv AT bhavsardharas rphplcmethodforsimultaneousestimationoftenofovirdisoproxilfumaratelamivudineandefavirenzincombinedtabletdosageform
AT patelbhavinin rphplcmethodforsimultaneousestimationoftenofovirdisoproxilfumaratelamivudineandefavirenzincombinedtabletdosageform
AT patelchhaganbhain rphplcmethodforsimultaneousestimationoftenofovirdisoproxilfumaratelamivudineandefavirenzincombinedtabletdosageform